1 published article · Updated continuously
22 trials tracked for lower urinary tract symptoms: 8 in phase 3 or 4 and 3 with published results. The most-cited published study has 67 citations.
Showing the 22 most-cited and recently-updated of 22 trials. Browse the full registry →
Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.
New evidence indicates that self-administered nitrous oxide is an available intervention for lower urinary tract symptoms 1. Tamsulosin has been shown to reduce the International Prostate Symptom Score (IPSS) by values ranging from 9.2 to 18.7 3 and significantly decrease the Urinary Growth Factor to Creatinine Ratio (GF/Cr) by -19.61 2. Additionally, tamsulosin was associated with a reduction in the mean number of micturitions per 24 hours (-1.1 to -2.3) and a significant reduction in the Total Urgency Frequency Score (TUFS) (-4.4 to -8.1) 8.
A fixed-dose combination of tamsulosin hydrochloride and solifenacin succinate resulted in a reduction of 9.0 in total IPSS, a reduction of 10.1 in TUFS, and a decrease of 2.5 in the mean number of micturitions per 24 hours 7. In contrast, placebo groups showed no significant improvement or were associated with minor changes in IPSS (6 to 7) 5 or erectile function scores 6. Furthermore, tamsulosin demonstrated high adherence rates, with over 85% of patients following label instructions and over 93% taking no more than one capsule per day 12.
A combination of tolterodine and tamsulosin showed a statistically significant reduction in the frequency of urination at 6 weeks (p=<.0001) and between 6 to 12 weeks (p=.0013), though the change from baseline to 12 weeks did not reach statistical significance (p=0.2933) 4.
AI synthesis of 10 cited trials, updated Jun 28, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.
